PPBT - Purple Biotech logo

Purple Biotech

PPBT

Purple Biotech develops cancer therapies targeting tumor immune evasion and drug resistance. Its pipeline includes monoclonal antibodies and small molecules in clinical trials for pancreatic cancer and head/neck cancers, among others.

โš•๏ธ Healthcare NASDAQ Listed 2015 $ USD
$1,000 invested 10 years ago โ†’$0today

Score Overview

1 Year
Scoreโ€”
Net Growth6.62%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score3.5
Net Growth-34.03%
Net Trend33%
Net Income Consistencyโ€”
Rev Growth100.00%
Rev Trend20%
Revenue Consistencyโ€”
10 Years
Scoreโ€”
Net Growth-103.22%
Net Trend38%
Net Income Consistency
Rev Growthโ€”
Rev Trend22%
Revenue Consistency
All Time
Scoreโ€”
Net Growth-486.39%
Net Trend33%
Net Income Consistency
Rev Growthโ€”
Rev Trend22%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Purple Biotech has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. PPBT does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-21
$ 1.15โ€”
1 Year2025-10-21
$ 5.76-80.03%
5 Years2021-10-21
$ 930.00-99.88%
10 Years2016-10-21
$ 7.9K-99.99%
All Time2015-11-20
$ 6.38K-99.98%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 0.00-$ 24M$ 6M
2025$ 0.00-$ 26M$ 9M
2024$ 0.00-$ 7M$ 8M
2023$ 195.8K$ 15M
2022-$ 910K-$ 21M$ 32M
2021-$ 320K-$ 18M$ 47M
2020$ 1M-$ 27M$ 57M
2019$ 1M-$ 5M$ 6M
2018$ 1M-$ 5M$ 5M
2017$ 100K-$ 12M$ 3M
2016-$ 12M$ 14M
IPO2015-$ 4M$ 10M
PPBT - Purple Biotech logo

Purple Biotech fundamental performance

Between 2020 and 2025, revenue declined from $ 1M to $ 0.00 and net income went from -$ 27M to -$ 26M. Revenue increased in 1 of those 5 years; net income in 2.

Purple Biotech currently holds a 5-year HDB Score of 3.5 out of 10. How the HDB Score is calculated.

Membership

Explore PPBT with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,118 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies